These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7681121)

  • 61. Re: The Effects of Combination Therapy With Dutasteride and Tamsulosin on Clinical Outcomes in Men With Symptomatic Benign Prostatic Hyperplasia: 4-Year Results From the CombAT Study.
    Kaplan SA
    J Urol; 2011 Apr; 185(4):1384-5. PubMed ID: 22115487
    [No Abstract]   [Full Text] [Related]  

  • 62. Transurethral resection of the prostate: still the gold standard?
    Ramsey EW
    Can J Surg; 1993 Feb; 36(1):9-10. PubMed ID: 7680274
    [No Abstract]   [Full Text] [Related]  

  • 63. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia.
    McConnell JD
    Urol Clin North Am; 1990 Aug; 17(3):661-70. PubMed ID: 1695786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Re: comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
    Kaplan SA
    J Urol; 2014 Feb; 191(2):423-4. PubMed ID: 24411885
    [No Abstract]   [Full Text] [Related]  

  • 66. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
    Mačukat IR; Spanjol J; Orlič ZC; Butorac MZ; Marinovič M; Ćupič DF
    Coll Antropol; 2014 Sep; 38(3):835-9. PubMed ID: 25420363
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effects of 5α-reductase inhibition on benign prostatic hyperplasia treated by photoselective vaporization prostatectomy with the 120 Watt GreenLight HPS laser system.
    Strom KH; Gu X; Spaliviero M; Wong C
    J Am Coll Surg; 2011 Feb; 212(2):244-50. PubMed ID: 21183365
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Dutasteride provides chemoprevention].
    Werner F
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):18. PubMed ID: 23646395
    [No Abstract]   [Full Text] [Related]  

  • 70. [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)].
    Aliaev IuG; Vinarov AZ; Lokshin KL; Spivak LG
    Urologiia; 2006; (6):83-6. PubMed ID: 17315721
    [No Abstract]   [Full Text] [Related]  

  • 71. Re: Rates of Prostate Surgery and Acute Urinary Retention for Benign Prostatic Hyperplasia in Men Treated with Dutasteride or Finasteride.
    Kaplan SA
    J Urol; 2017 Oct; 198(4):719-721. PubMed ID: 28905745
    [No Abstract]   [Full Text] [Related]  

  • 72. Hormonal manipulation of benign prostatic hyperplasia.
    Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
    Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Masumori N
    Int J Urol; 2015 Jun; 22(6):589. PubMed ID: 25827235
    [No Abstract]   [Full Text] [Related]  

  • 74. Editorial Comment from Dr Oh-oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Oh-Oka H
    Int J Urol; 2015 Jun; 22(6):588. PubMed ID: 25827197
    [No Abstract]   [Full Text] [Related]  

  • 75. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
    Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
    Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is There an Association between 5a Reductase Inhibitors and Metabolic Syndrome? A Narrative Review of the Literature.
    Ziogou A; Giannakodimos A; Mitakidi E; Konstantinos T; Giannakodimos I
    Rev Recent Clin Trials; 2024; 19(4):229-235. PubMed ID: 38910423
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The tested combination is recommended. Are 5-alpha reductase inhibitors interchangeable?].
    MMW Fortschr Med; 2003 Jul; 145(27-28):59. PubMed ID: 14587194
    [No Abstract]   [Full Text] [Related]  

  • 78. Two for the price of one?
    Wyllie M
    Br J Pharmacol; 2005 Jan; 144(1):1-2. PubMed ID: 15644862
    [No Abstract]   [Full Text] [Related]  

  • 79. Editorial comment.
    Madersbacher S
    Urology; 2011 Sep; 78(3):646-7. PubMed ID: 21884913
    [No Abstract]   [Full Text] [Related]  

  • 80. Chemoprevention of prostate cancer.
    Walsh PC
    N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.